Hangzhou Tigermed Consulting Co., Ltd
3347.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$54.09B
Close$
$27.74
34.4% downside
Current Fair Value
34.4% downsideOvervalued by 34.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $54.09 Billion |
|---|---|
| Enterprise Value | $54.38 Billion |
| Dividend Yield | $0.14 (0.23%) |
| Earnings per Share | $1.03 |
| Beta | 0.34 |
| Outstanding Shares | 836,354,301 |
Return
| Return on Equity | 0.48% |
|---|---|
| Return on Assets | 0.33% |
| Return on Invested Capital | 6.78% |
Valuation & Multiples
| P/E Ratio | 689.75 |
|---|---|
| PEG | -221.39 |
| Price to Sales | 5.29 |
| Price to Book Ratio | 1.57 |
| Enterprise Value to Revenue | 7.48 |
| Enterprise Value to EBIT | 31.78 |
| Enterprise Value to Net Income | 586 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$0.25
Average shareholder expectationRevenue Estimate
$2.17 B
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
$0.36
Average shareholder expectationRevenue Estimate
$2.30 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hangzhou Tigermed Consulting Co., Ltd
11,984 employees
CEO: Xiao Chun Cao Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as ...